 Chemotherapy, Adjuvant
"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 3 | 3 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 4 | 4 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 6 | 6 | | 2001 | 0 | 3 | 3 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 3 | 3 | | 2004 | 0 | 6 | 6 | | 2005 | 2 | 9 | 11 | | 2006 | 1 | 6 | 7 | | 2007 | 1 | 12 | 13 | | 2008 | 1 | 9 | 10 | | 2009 | 0 | 6 | 6 | | 2010 | 0 | 9 | 9 | | 2011 | 0 | 3 | 3 | | 2012 | 0 | 6 | 6 | | 2013 | 0 | 15 | 15 | | 2014 | 0 | 12 | 12 | | 2015 | 0 | 14 | 14 | | 2016 | 0 | 16 | 16 | | 2017 | 2 | 18 | 20 | | 2018 | 3 | 16 | 19 | | 2019 | 2 | 13 | 15 | | 2020 | 6 | 10 | 16 | | 2021 | 3 | 6 | 9 | | 2022 | 0 | 8 | 8 | | 2023 | 0 | 12 | 12 | | 2024 | 0 | 8 | 8 | | 2025 | 0 | 12 | 12 | | 2026 | 0 | 7 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23; 395(4):338-348.
-
Stoop TF, Croce C, Ishida H, Ali M, Javed AA, Halimi A, Oba A, Groot Koerkamp B, Leonhardt CS, Thiels CA, Rangelova E, Sparrelid E, Sotirova I, Leiting JL, Tauchi J, Kobayashi K, Klos M, Beuk LPM, Genova L, Mastronardi M, Kendrick ML, Mughal NA, Busch OR, Franklin O, Larsson P, Klaiber U, Schulick RD, Theijse RT, Strobel O, Ghorbani P, de Wilde RF, Rodriguez Franco S, Sugawara T, Wilmink JW, Messersmith W, Besselink MG, Wolfgang CL, Inoue Y, Truty MJ, Del Chiaro M. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international multicentre retrospective study. BJS Open. 2026 May 12; 10(3).
-
Molnár A, Rodriguez Franco S, Sugawara T, Croce C, Kirsch MJ, Svensson J, Stoop TF, Messersmith WA, Schulick RD, Franklin O, Del Chiaro M. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. HPB (Oxford). 2026 Jul; 28(7):932-944.
-
Wach MM, Bank H, Kelly K, Le T, Derby J, Nunns G, Zureikat AH, Bartlett DL, Ahrendt SA, Pingpank JF, Choudry HA, Ongchin M. A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC. Ann Surg Oncol. 2026 Jul; 33(7):6175-6184.
-
Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
Pellegrini R, Del Chiaro V, Franco SR, Ishida H, Nara A, Galvez KN, Mungo B, Del Chiaro M, Schulick RD. Histopathologic Subtype as a Determinant of Prognosis and Chemotherapy Benefit in Resected Ampullary Adenocarcinoma. J Hepatobiliary Pancreat Sci. 2026 Jul; 33(7):537-547.
-
Haw Y, Krings G, Hsiao WY, Zhan H, Hou Y, Zhang G, Zhang H, Wei S, Yang W, Laé M, Post MD, Liu Y, Shamir ER, Rosa M, Siziopikou K, Schnitt S, Chen YY, Li X. Clinicopathologic Analyses of 34 Cases of High-Grade Serous-Like Carcinoma (HG-SL-Ca) of the Breast. Am J Surg Pathol. 2026 May 01; 50(5):543-549.
-
Mattei J, Ruitao L, Davies MA, Wong MK, Diab A, Haydu LE, Patel SP, Amaria RN, McQuade JL, Tawbi H, Burton EM, Glitza IC. Adjuvant therapy in mucosal melanoma: a single-center experience and review of the literature. Melanoma Res. 2026 02 01; 36(1):31-42.
-
Kopp RM, Massari F, Grande E, Schieber TJ, Ürün Y, Kopecký J, Molina-Cerrillo J, Basso U, Kucharz J, Büttner T, Pichler R, Fiala O, Myint ZW, Galli L, Buchler T, Rizzo M, Bolek H, Bourlon MT, Conteduca V, Pinto A, Rizzo A, Rosellini M, Roviello G, Zgura A, Mollica V, Partl A, Yildirim A, Akova U, Buti S, Monteiro FSM, Soares A, Porta C, Bilen MA, Li H, Santoni M. Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study. Cancer Immunol Immunother. 2025 Nov 14; 74(12):374.
-
Ishida J, Franklin O, Franco SR, Ishida H, Khomiak A, Sugawara T, Grandi S, Stoop TF, Kirsch MJ, Schulick RD, Del Chiaro M. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. HPB (Oxford). 2026 Mar; 28(3):369-378.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|